A Case Report: Successful Treatment of Meningeal Metastasis with Concurrent Whole Brain Radiotherapy and Erlotinib in a Patient with Non-small Cell Lung Cancer

J Huang¹, X-R Dong¹, H-D Lu², L Liu¹

ABSTRACT

We report a case of successful treatment with erlotinib of a patient with non-small cell lung cancer (stage IV) and meningeal metastasis. Combined treatment with whole brain radiotherapy (WBRT) and erlotinib mitigated neurologic symptoms of the patient. Magnetic resonance imaging showed reduction of the brain metastasis. Partial remission was observed by chest computed tomography (CT) scan after six months of erlotinib therapy.

Key words: Erlotinib, magnetic resonance imaging, non-small cell lung cancer, whole brain radiotherapy

INTRODUCTION

Meningeal metastasis occurs in approximately 5% of breast cancers, which produces high neurologic morbidity and mortality (1). Therapies usually include radiotherapy, intrathecal chemotherapy and systemic chemotherapy. However, treatment is often ineffective. Most untreated patients can only survive a median of four to six weeks (2). Standard treatment only increases the median survival to 3–6 months (3). Combined chemotherapy and radiotherapy may produce an enhanced effect.

CASE REPORT

We report a patient with meningeal metastasis responding to concurrent whole brain radiotherapy and erlotinib. A 67-year old Chinese man without a smoking history was diagnosed with T1N2M1 stage IV non-small-cell lung cancer (NSCLC) with bone metastasis in November 2007. During a medical examination in November 2007, the patient was found to have a mass in his right upper lung. After undergoing bronchoscopy and position emission tomography-computed tomography (PET-CT), he was diagnosed with adenocarcinoma of the lung with bone metastasis. The patient immediately received first-line treatment with carboplatin (area under the curve 6) and paclitaxel (175 mg/M² every three weeks). After six cycles of chemotherapy, a partial remission of the primary disease in his chest was achieved as demonstrated by CT scan.

In September 2008, however, he experienced headache, progressive visual loss, unsteady gait and temporary absence of consciousness. Magnetic resonance imaging showed a mass in the right temporal lobe with mass effect. He was referred for whole brain radiotherapy. Erlotinib was added to his treatment regimen.

ACKNOWLEDGMENTS

This research was supported by grants from the National Natural Science Foundation of China (No. 81272453, No. 81272454).
seizure. Brain magnetic resonance imaging (MRI) with a Gd-DTPA administration showed an abnormal meningeal enhancement in the occipital lobe on T1-weighted imaging (Fig. 1A) and papilloedema was noted on funduscopic examination.

A lumbar puncture was performed and the cerebrospinal fluid (CSF) proved to be positive for adenocarcinoma cells. Computed tomography imaging confirmed tumour progression in the right lung (Fig. 1B), coupled with abnormal levels of tumour markers detected by medical laboratory tests (Table).

Table: The expression of serum tumour markers before and during treatment

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>CEA (ng/ml)</td>
<td>36.8 ± 4.18</td>
<td>13.3 ± 2.69</td>
</tr>
<tr>
<td>CA-125 (U/ml)</td>
<td>67.8 ± 7.54</td>
<td>20.9 ± 3.71</td>
</tr>
<tr>
<td>CA-199 (U/ml)</td>
<td>103.4 ± 11.86</td>
<td>14.1 ± 1.95</td>
</tr>
</tbody>
</table>

· Compared with serum tumour marker levels before treatment, the differences are statistically significant.

Due to his poor performance status, the patient received whole brain radiotherapy (WBRT) [36Gy/12F] with concurrent Tarceva 150 mg daily. After a week’s treatment, his headaches began to ease and then disappeared, while his sight improved gradually. The levels of tumour markers returned to normal in late October 2008 (Table). After completion of the WBRT, MRI with Gd-DTPA administration indicated that the high-intensity signals were largely diminished in T1-weighted imaging (Fig. 2A), and the patient was discharged at the end of October 2008 and continued to receive erlotinib as an outpatient.

When the patient returned for review with CT result in March 2009, he presented with a significantly improved physical condition. The chest CT scan (Fig. 2B) showed that there was partial response as assessed by the RECST guidelines. Treatment was well tolerated, and the adverse effects were minimal rash and low-grade diarrhoea. The patient had good performance status, and the size of the primary lung tumour did not enlarge for more than one year (Fig. 2C, chest CT scan in late October 2009).

DISCUSSION

Brain metastasis is a common complication in patients suffering from NSCLC. Autopsy studies have shown that approximately 44% of all patients with NSCLC have brain metastasis during the course of the illness.

Meningeal metastasis was first recognized by Eberth in 1870 and was initially thought to be rare as it was uncommonly diagnosed before death. However, the reported incidence of this advanced complication is likely to increase due to advances in neuroimaging techniques and the long survival of cancer patients.

The characteristics of the disease involve various levels of the nervous system, including encephalic, cranial or spinal nerve and spinal symptoms. Sudden loss of vision or hearing is the initial sign of the disease which may progress rapidly. Headache, changes in mental status, cranial nerve palsies, back or radicular pain, incontinence, lower motor neurone weakness, and sensory abnormalities are all common presenting findings.

Although CT and nuclear magnetic resonance may aid in the diagnosis of this condition, only the presence of malignant cells in the CSF is considered to be the gold standard in the diagnosis of meningeal metastasis (4).

The treatment for meningeal metastasis includes radiotherapy, intrathecal chemotherapy and systemic chemotherapy. However, no effective drug for NSCLC has been approved as safe for intrathecal injection. Whole brain radiotherapy, the so-
called ‘gold-standard in the treatment of brain metastasis’, is effective, but its impact on survival seems to be limited (5).

Erlotinib (Tarceva, OSI–774) is an orally available small-molecule inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase. Similar to gefitinib, erlotinib is designed to block tumour cell growth by targeting the protein of human epidermal growth factor receptor 1 (HER1/EGFR). Erlotinib has demonstrated a survival benefit in patients treated for lung cancer in phase III trials. It was approved by the Food and Drug Administration (FDA) in 2004 for the treatment of locally advanced or metastatic NSCLC that has failed at least one prior chemotherapy regimen.

Eight case reports have described the clinical efficacy of Tarceva in patients with central nervous system (CNS) metastasis (6). In most reports, patients’ brain lesions responded to Tarceva. Rash was documented in several reports including one case of acute generalized exanthematous pustulosis (AGEP), a case of Grade 3 acneiform skin rash, radiodermatitis, elevated liver enzymes, vertigo and one fatal case of bilateral subdural haemorrhage.

In a phase I study by Lind et al, WBRT with concurrent erlotinib was well tolerated in patients with brain metastasis from NSCLC (7). Mairovitz et al published a case report of a patient diagnosed with NSCLC with bone and brain metastasis, who presented a complete cerebral response for 17 months with erlotinib prescribed as a third line therapy (8).

In the present study, erlotinib showed good effect and good tolerance on metastatic lesions in the CNS from NSCLC. However, there are still few reports about meningeal metastasis, partly due to its low incidence and poor effect. In this case, the patient was treated with WBRT in combination with erlotinib. Then erlotinib was used as maintenance treatment. The patient has survived for more than one year without progression. No serious adverse effect was found during the treatment. These results suggest that WBRT in combination with erlotinib may be a beneficial therapy for meningeal metastasis in NSCLC and deserves further study.

REFERENCES